Cipla
Cipla News
ICICI Bank shares rise by over 14% after record high quarterly profit
Total income also rose to Rs 26,031 crore in July-September period of 2021-22, as against Rs 23,651 crore in the same quarter of the previous fiscal year, ICICI Bank said in a regulatory filing
Moderna's COVID-19 vaccine gets approval for restricted emergency use, confirms Centre
Earlier news agency PTI had reported that the DCGI has granted permission to Cipla to import Moderna's COVID-19 vaccine for restricted emergency use in the country.
Bombay HC asks Maharashtra govt to scrutinise Sonu Sood, Cong MLA Zeeshan Siddique's role in procuring anti-COVID drugs
The Bombay High Court also noted that "these people (celebrities) projected themselves as some kind of messiahs without verifying if the drugs were spurious or if the supply was legal."
DCGI eases norms for clearing foreign-made COVID-19 vaccines to bolster availability of shots
These exemptions have been made in light of the huge vaccination requirements in India in the wake of the recent surge of COVID-19 cases and the need for increased availability of imported vaccines to meet national requirements
Roche launches COVID-19 'Antibody Cocktail' in India at Rs 59,750 per dose; Cipla to market drug in country
In a joint statement, the pharma giants said that the second batch of the Antibody Cocktail (Casirivimab and Imdevimab) will be available by mid-June
Mizoram records first COVID-19 fatality as India tally nears 80 lakh; active cases below 7 lakh for sixth day
Meanwhile, the Delhi government announced that schools will remain closed till further orders, and the DGCA extended the suspension of international passenger flights till 30 November
Cipla confirms collaboration with CSIR, IICT, ICMR to develop COVID-19 treatment
The Mumbai-based firm is also ramping up manufacturing of drugs required to treat COVID-19, like Lopinavir-Ritonavir and Hydroxychloroquine
Cipla's remdevisir to cost Rs 4,000 per 100 mg vial in India; pricing among lowest globally: Report
Cipla India business chief executive officer Nikhil Chopra said that the company was launching Cipremi commercially on Wednesday and aims to supply over 80,000 vials within the first month, but did not give details on pricing.
Health
Mylan's remdesivir to cost Rs 4,800 per 100 mg vial in India, 80% cheaper than price tag in wealthy nations
Gilead priced remdesivir at $2,340 per patient for rich nations and agreed to send nearly all of its supply of the drug to the United States over the next three months
Sensex drops 260 points, Nifty settles below 9,050-mark at close of trading session; banking, financial stocks drag
Sensex tumbled 260 points on Friday, dragged by losses in banking and financial stocks as RBI's rate cut and other measures to prop up the economy failed to meet market expectations.
Cipla submits application with USFDA for generic version of asthma drug
Drug major Cipla on Monday said it has submitted an application with the US health regulator for a generic version of GSK's Advair Diskus, which is used in the treatment of asthma and other respiratory disorders
Sensex plunges over 800 points, Nifty slumps 227 points in early trade as economic package fails to impress
After hitting a low of 30,265.67, the Sensex was trading 731.91 points or 2.35 percent lower at 30,365.82. Similarly, NSE Nifty slumped 226.90 points, or 2.48 percent, to 8,909.95.
Cipla inks licensing pact with Gilead Sciences for potential COVID-19 treatment drug remdesivir
Homegrown pharma major Cipla Ltd on Wednesday said it has signed a non-exclusive licensing agreement with Gilead Sciences Inc for manufacturing and distribution of investigational drug remdesivir, a potential therapy for COVID-19
Hetero inks licensing agreement with Gilead for manufacturing, distribution of remdesivir
Domestic pharma major Hetero on Wednesday said it has entered into a licensing agreement with Gilead Sciences Inc for manufacturing and distribution of remdesivir, a potential therapy for COVID-19
Gilead ties up with 5 generic drugmakers in India, Pakistan for COVID-19 drug supply; licensees to set price for product
Gilead’s antiviral drug remdesivir earlier this month received the US Food and Drug Administration’s emergency use authorization to treat COVID-19 patients.
Markets end in red: Sensex plummets 2,002 points, Nifty suffers heavy loss of over 560 points; ICICI Bank top loser
Sensex plunged 5.94 percent or 2,002 points on Monday, tracking massive selloffs in global markets amid rising US-China tensions.
Markets end week with gain of 7%: Sensex soars 997 points to end at 33,717, Nifty surges to 9,860; Tata Motors, ONGC major gainers
The NSE Nifty 50 index ended 3.2 percent higher at 9,859. The index was up 7.7 percent this week.
Bears grip markets after two sessions of bullish show: Sensex, Nifty end on negative note; all sectoral indices close in red
Sensex, Nifty end on negative note after a volatile session on 24 April
Stock Market Today Latest Updates: Market at 3-week high as Sensex soars over 1,200 points, Nifty above 9,100; M&M zooms nearly 17%
Stock Market Today LIVE Updates: Bourses erase early gains; Sensex slips 250 points, Nifty below 9,000-mark; bank stocks in green
Bourses track Asian peers: Sensex rallies over 900 points, Nifty reclaims 9,000-mark; HDFC, Maruti among top gainers
After hitting a high of 30,847.10, the 30-share Sensex was trading 925.67 points or 3.10 per cent higher at 30,819.63.